Differential effect of corticosteroid treatment on Influenza, SARS, MERS, and

SARS-CoV-2 patients: A meta-analysis and systematic review

Authors: Sobur Ali^{1a}, Salman Zahir Uddin^{1a}, Md. Nayem Dewan², M Moniruzzaman¹, Mir Himayet Kabir³, Mohammad Rafiqul Islam⁴, Hossain Monir¹, Shanewaz Hossan⁵, Tanvir Noor Nafiz¹, Rumana Rashid⁶, Khan Mohammad Imran^{7*}

Suppl table ST1. PRISMA Checklist.

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-7
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	7

METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	8
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8-9
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	9-10
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9-10
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	10
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	10
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias , selective reporting within studies).	10

Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	10
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	11
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	11
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	14
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	12-13
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	12-13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	14
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12-13
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	15-19
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	17-18

Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19

Suppl table ST2. Characteristics of study and patients.

	Author	Title	Year	Type of study	Type of Virus	Corticosteroid used	Patient in treatment arm/ control arm	Mortality rate (treated/control)	Secondary infection rate (Bacterial) (Treated/control)	Secondary infection rate (Viral) (Treated/ control)	M/F % of total patient	M/F% of Treated/control	Mean age of total patient/dead patient	length of hospital stay (treated/control)	length of ICU stay (treated/control) days	Number (%) of patient required Mechanical ventilation (Treated/control)	Mechanical Ventilation (Treated/control)	Viral clearance control/ cortico
1	Yam et al., 2007	Corticosteroid Treatment of Severe Acute Respiratory Syndrome in Hong Kong	2007	Retrospective study (Inconclusive)	SARS	hydrocortisone; prednisolone; methylprednisolone	1188/99	17%(202/1188)/ 28.3% (28/99)	4.2%/2%		43/57	42/58/ 52/48	>18 yrs/>18 yrs					
2	Boudreault et al., 2011	Impact of Corticosteroid Treatment and Antiviral Therapy on Clinical Outcomes in Hematopoietic Cell Transplant Patients Infected with Influenza Virus	2011	Retrospective single- centered study	influenza	prednisone/ methylprednisolone, beclomethasone dipropionate (BDP)	80/63	12.5% (10/80)/ 11.11% (7/63)	21% (63) Control, 19 (43)% low, 19(37)% high dose		83/60	58%/42% /57%/43%	42 (31 - 53) - median/42			4(10%)/9 (14%)	-	-/7 (5- 12)
3	Moreno et al., 2018	Corticosteroid Treatment in Critically III Patients With Severe Influenza Pneumonia: A Propensity Score Matching Study	2018	prospective cohort study	influenza A(H1N1)pdm09 virus	578 (95.7%) methylprednisolone; 23 (3.8%) prednisolones; 3 (0.5%) dexamethasone	604/1242	27.50%/18.80%	23%/20%	7.6% / 6.4 %	59.37/40.63	59.1/40.9/59.5/ 40.5%	52/ No data	All were ICU patients	8-Oct	506 (83.8%)/921 (74.2%)	8 (3-17)/ 8 (3- 16)	
4	Diaz et al., 2012	Corticosteroid Therapy in Patients With Primary Viral Pneumonia Due to Pandemic (H1N1) 2009 Influenza	2012	Prospective, observational	Influenza (H1N1)	corticosteroid	136/136	18.38%/17.37%	-	-	55/45	57.60%/50.7% (69/67)	43/ No data			-	9.44 (14.36)/ 9.47 (13.11)	
5	Martin- Loeches et al., 2011	Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection	2011	Prospective, observational	H1N1 Influenza A	corticosteroid	126/94	46.00%/18.10%	26.2/13.8%		113/107	54/46/ 47.9/52.1	43.26(11.2)/ 46.1 (17.4)		12.9+- 14/10.8+-9.8			
6	Delaney et al., 2016	The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)- related critical illness	2016	observational cohort study	H1N1pdm09	prednisone, Hydrocortisone and Methylprednisolone, Cortisone, Dexamethasone	280/327	25.50%/16.40%	87 (31.1%) / 118 (36.1%)	No data	48.1/51.9	45.7/54.3/ 50.1/49.9	47.4/ No data	All were ICU patients	18.5/14.8	260 (93.5)/ 275 (85.4)	$\begin{array}{c} 15.5 \pm 10.1 / 12.3 \\ \pm 10.1 \end{array}$	
7	Arabi et al., 2018	Corticosteroid Therapy for Critically ill Patients with the Middle East Respiratory Syndrome (retrospective cohort)	2018	retrospective cohort study	MERS-CoV	Hydrocortisone-methylprednisolone, dexamethasone, prednisolone	151/158	74.20%/57.60%	-	-	213/94	70.9/29.1/ 67.1/22.9	56.7/ No data	21.0 (13-38) /15.0 (8-30)	12.5 (8-23) / 7.0 (5-13)	93.4% (141/151)/ 76.6% (121/158)		
8	Kim et al., 2011	Corticosteroid Treatment in Critically III Patients with Pandemic Influenza A/H1N1 2009 Infection	2011	cohort study	Influenza A H1N1	prednisolone, Hydrocortisone and Methylprednisolone	107/138	58%/27%	57%/22%	-	54.69/45.31	57/43/ 52.9/47.1	55.32/ No data	30.8 (36.9)/18.9 (20.0)	13.5 (13.2) /8.8 (9.2)	85% (91/107)/ 51% (71/138)	13.3 (13.2)/ 9.6 (10.0)	
9	Brun-Buisson et al., 2011	Early Corticosteroids in Severe Influenza A/H1N1 Pneumonia and Acute Respiratory Distress Syndrome	2011	retrospective analysis	Influenza A/H1N1	Hydrocortisone, Methylprednisolone, Prednisone	83/125	33.70%/16.80%	27.7% /34.4%		50.5%/49.5%	45.4%/56.6%/ 55.2%/44.8%	47 (35-55)/ 45 (42-56)		22/17		17 (10-29)/ 13 (8-24)	
10	Villar et al., 2020	Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial	2020	randomised controlled trial	None	dexamethasone	139/138	21/36	24/25		61/39		57				15.7/20.5	
11	Li et al., 2017	Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia	2017	Case-Control	Influenza A(H1N1) pdm09	Methylprednisolone, Dexamethasone, Hydrocortisone, Prednisolone	1055/1089	30 day: 22%, 60-day: 24.7%/ 30 day: 6.8%, 60- day: 7%	19.1%/4.1%		51.1/48.9	50.2/49.8/ 52/48	34.4/ No data	no data	no data	Invasive mechanical ventilation: 367 (34.8%)/49 (4.5%)	no data	
12	Cao et al., 2016	Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia	2016	cohort study	Influenza A (H7N9)	Methylprednisolone, Dexamethasone, Hydrocortisone	65/65	27(41.5%)/ 10 (15.3%)	49.4/41.6	-	70/30	70.8/29.2/ 69.2/30.8	58 (46-65) + 56 (43-68)	-	-	38/27	-	
13	Linko et al., 2011	Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland	2011	prospective observational study	Influenza A(H1N1)	methylprednisolone, Hydrocortisone	72/60	11%/2%	55.9/12.8%	n/a	n/a	64/36/65/35	n/a	24 [14–37]/ 15 [8–25]	13 [18–20]/4 [3–5]	50.70%/34.80%	6 (1-12)/0	
14	Lu et al., 2020	Adjuvant corticosteroid therapy for critically ill patients with COVID-19	2020	retrospective cohort study	SARS Cov2	methylprednisolone 1:5, dexamethasone 1:25)	151/93	52.30%/5.40%			52/48	55/45/48/52	62 (50-71)			78 (52%)/4 (4%)		
15	Hong et al., 2020	Corticosteroid treatment in patients with severe covid-19 pneumonia	2020	Retrospective cohort study	SARS-CoV-2	oral prednisone and systemic methylprednisolone.	93/84	53%/57%	-			-		-	-	38/93/10/84		
16	Liu et al., 2020	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19	2020	Retrospective cohort study	SARS-CoV-2	Methylprednisolone, Dexamethasone, Hydrocortisone, Prednisolone	124/124	37.9/37.9%	8.9%/5.6%					44147	44020			
17	Fernández- Cruz et al., 2020	A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality	2020	Retrospective Controlled Cohort Study	SARS-CoV-2	methylprednisolone	396/67	55/396/16/67	-	-	-	276/120/41/16	65.4	-	-	-	-	
18	Li et al., 2020	Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study	2020	retrospective cohort study	SARS-CoV-2		55/55	1.89/0%	89.1	23.6				23/15				11/18 day
19	Ma et al., 2020	Corticosteroid therapy for patients with severe novel Coronavirus disease 2019	2020	retrospective cohort study	SARS-CoV-2		47/25	4.2/8%		31/18				18.7/21		24/8	9.6/12.8	19.4/16.1
20	Dequin et al., 2020	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19	2020	RCT	SARS-CoV-2	hydrocortisone	76/73	14.7/27.4%		37.3%/41.1%	69.8/30.2		62.2			0.227/0.233		
21	Tomazini et al., 2020	Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial	2020	RCT	SARS-CoV-2	dexamethasone	151/148	56.3/61.5%	7.9/9.5	21.9/29.1							12.5/13.9	
22	Horby et al., 2020	Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report RECOVERY TRIAL	2020	RCT	SARS-CoV-2	dexamethasone	2104/4321	22.9/25.7%								228/400		
23	Angus et al., 2020	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID- 19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial	2020	RCT	SARS-CoV-2	hydrocortisone	278/101	28.05/33%										
24	Jeronimo et al., 2020	Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial	2020	RCT	SARS-CoV-2	Methylprednisolone	194/199	37.11%/38.19%			64.9/35.1	64.3/35.7/ 64.3/35.7	55	10 (7-13)/9 (7- 12)		66/194/67/199		



Suppl. figure S1. Effect of corticosteroid on Length of Mechanical Ventilation in days (Z=2.26, P=0.024, SMD: standard mean difference, SD: standard deviation, horizontal line express 95% CI, Diamond represents overall estimate from the meta-analysis, squares represent effect size for each study).



Suppl. figure S2. Effect of corticosteroid on the length of hospital stay (Z=3.16, P=0.002, SMD: standard mean difference, SD: standard deviation, horizontal line express 95% CI, Diamond represents overall estimate from the meta-analysis, squares represent effect size for each study).



Suppl. figure S3. Subgroup analysis of effect of corticosteroid on length of hospital stay for patients with H1N1 and MERS-CoV viral infections (SMD: standard mean difference, SD: standard deviation, horizontal line express 95% CI, Diamond represent overall estimate from the meta-analysis, squares represent effect size for each study).



Suppl. figure S4. Effect of corticosteroid on the length of ICU stay (Z=3.07, P=0.002, SMD: standard mean difference, SD: standard deviation, horizontal line express 95% CI, Diamond represents overall estimate from the meta-analysis, squares represent effect size for each study).



Suppl. figure S5. Subgroup analysis of effect of corticosteroid on length of ICU stay for patients with H1N1 and MERS-CoV viral infection (SMD: standard mean difference, SD: standard deviation, horizontal line express 95% CI, Diamond represent overall estimate from the meta-analysis, squares represent effect size for each study).



Suppl. figure S6. Funnel plot analysis of selected articles to check publication bias.

Egger's test (Egger, Smith et al. 1997):

Intercept: 2.788 Confidence interval: - -0.348 to -5.924 t statistic: 1.766 P value: 0.09

Interpretation:

We can see that the P value of Egger's test is not significant (P > 0.05), which suggest that there is no evidence of publication bias.

Egger, M., et al. (1997). "Bias in meta-analysis detected by a simple, graphical test." <u>Bmj</u> **315**(7109): 629-634.

Study	A. Selection	1			В.	C. Outcome		
					Comparability of cohort			
	Represent- activeness of exposed cohort	Selection of non- exposure	Ascertainment of exposure	Outcome not present at start		Assessment of exposure	Follow- up long enough?	Adequacy of Follow- up
Yam 2007	☆	☆	☆	☆		☆	☆	☆
Boudreault 20111	☆	☆	☆	☆		\$		☆
Moreno 2018	☆	☆	\$	☆	**	☆		\$
Diaz 2012	☆	☆	☆	☆		☆	☆	☆
Martin- Loeches 2018	*	☆	☆	\$		*		\$
Delaney 2016	☆	☆	☆	☆		☆		☆
Lu 2020	☆	☆	☆	☆	☆☆	☆		☆
Arabi 2018	☆	☆	☆	☆		☆	☆	☆
Kim 2011	☆	☆	☆	☆	$\diamond \diamond$	☆	☆	☆
Brun- Buisson 2011	*	☆	☆	\$	**	*		☆
Li 2017	☆	☆	☆	☆	☆☆	☆	☆	☆
Cao 2016	☆	☆	☆	☆	☆☆	☆	☆	☆
Linko 2011	☆	☆	☆	☆		☆		☆
Hong et al., 2020	☆	☆	☆	☆	☆	☆	☆	☆
Liu et al., 2020	☆	☆	☆	☆	**	*		☆
Fernández- Cruz et al., 2020	☆	☆	☆	*		*	☆	\$
Li et al., 2020	☆	☆	\$	☆	**	☆	☆	☆
Ma et al., 2020	☆	☆	☆	☆		☆		☆

Suppl. Table ST3: Risk of bias of included Observational study

Stars indicate the scores assigned to each study

Study	Sequence	Allocation	Blinding	Blinding	Missing	Other	Overall
	Generation	Sequence	(Performance	(Outcome	Outcome	Bias	Bias
		Concealment	bias)	measurement)	Data		
Villar 2020	Low	Low	Low	Low	Low	Probably	Low
						Low	
Dequin et	Low	Low	Low	Low	Low	Probably	Low
al., 2020						Low	
Tomazini et	Low	Low	Low	Low	Low	Probably	Low
al., 2020						Low	
Horby et al.,	Low	Low	Low	Low	Low	Probably	Low
2020						Low	
Angus et al.,	Low	Low	Low	Low	Low	Probably	Low
2020						Low	
Jeronimo et	Low	Low	Low	Low	Low	Probably	Low
al., 2020						Low	

Suppl. Table ST4: Risk of bias of included randomized controlled trials stud	lies
--	------